Omeros Corp entered an agreement on October 10, 2025, selling rights for its lead drug, zaltenibart, to Novo Nordisk for up to $2.1 billion, including a $240 million upfront payment. This transaction restricts Omeros from developing products targeting MASP-3, but allows it to continue some related research.